Multicentre, phase II, open-label, single-arm study evaluating the preliminary efficacy, safety and tolerability of atezolizumab in association with palliative radiotherapy in adult patients diagnosed with advanced (stage IV) NSCLC, irrespective of PD-L1 status, and who have oligoprogressed to both immunotherapy with an anti PD-1 agent (e.g., pembrolizumab or nivolumab) and 1 line of chemotherapy.
Description: Percentage of patients with a complete response or partial responseMeasure: Objective Response Rate Time: 3 months
Description: Time in months from the first day of study treatment to the date of deathMeasure: Overall Survival Time: 12 months
Description: Time in months from the first day of study treatment until the first evidence of tumour progressionMeasure: Progression Free-Survival Time: 12 months
Single Group Assignment
There is one SNP
Inclusion Criteria: - Signed Informed Consent Form - Histologically or cytologically confirmed diagnosis of metastatic (Stage IV) - NSCLC as per the American Joint Committee on Cancer (AJCC) 8th edition - No sensitizing EGFR mutation (L858R or exon 19 deletions), ALK fusion oncogene or ROS1 rearrangement detected - Progressing to one line of chemotherapy defined as follows: 1. --- L858R ---